Megan K Beckett1, Marc N Elliott2, J Quentin Clemens3, Brett Ewing2, Sandra H Berry4. 1. RAND Health, RAND, Santa Monica, California. Electronic address: beckett@rand.org. 2. RAND Health, RAND, Santa Monica, California. 3. Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan. 4. Survey Research Group, RAND, Santa Monica, California.
Abstract
PURPOSE: We describe differences in work participation and income by bladder symptom impact and comorbidities among women with interstitial cystitis/bladder pain syndrome. MATERIALS AND METHODS: Cross-sectional data from 2,767 respondents younger than 65 years identified with interstitial cystitis/bladder pain syndrome symptoms were analyzed. The data were taken from the RAND Interstitial Cystitis Epidemiology (RICE) survey, and included retrospective self-reports of interstitial cystitis/bladder pain syndrome impact, severity, years since onset, related comorbidities (depressive symptomatology, number of conditions), work participation and income, and personal characteristics. Multiple regressions predicted 5 current work outcomes of works now, kept from working by pain, missed work days, days worked when bothered by symptoms and real income change since symptom onset. RESULTS: Controlling for work status at symptom onset and personal characteristics, greater bladder symptom impact predicted a greater likelihood of not now working, kept more days from working by pain, missed more work days and working more days with symptoms. More depressive symptomatology and greater number of comorbidities predicted reduced work participation. Women experienced no growth in real income since symptom onset. Measures of symptom severity were not associated with any of the economic outcomes. CONCLUSIONS: Greater interstitial cystitis/bladder pain syndrome symptom impact, depressive symptomatology and count of comorbidities (but not symptom severity) were each associated with less work participation and leveling of women's long-term earnings. Management of bladder symptom impact on nonwork related activities and depressive symptomatology may improve women's work outcomes.
PURPOSE: We describe differences in work participation and income by bladder symptom impact and comorbidities among women with interstitial cystitis/bladder pain syndrome. MATERIALS AND METHODS: Cross-sectional data from 2,767 respondents younger than 65 years identified with interstitial cystitis/bladder pain syndrome symptoms were analyzed. The data were taken from the RAND Interstitial Cystitis Epidemiology (RICE) survey, and included retrospective self-reports of interstitial cystitis/bladder pain syndrome impact, severity, years since onset, related comorbidities (depressive symptomatology, number of conditions), work participation and income, and personal characteristics. Multiple regressions predicted 5 current work outcomes of works now, kept from working by pain, missed work days, days worked when bothered by symptoms and real income change since symptom onset. RESULTS: Controlling for work status at symptom onset and personal characteristics, greater bladder symptom impact predicted a greater likelihood of not now working, kept more days from working by pain, missed more work days and working more days with symptoms. More depressive symptomatology and greater number of comorbidities predicted reduced work participation. Women experienced no growth in real income since symptom onset. Measures of symptom severity were not associated with any of the economic outcomes. CONCLUSIONS: Greater interstitial cystitis/bladder pain syndrome symptom impact, depressive symptomatology and count of comorbidities (but not symptom severity) were each associated with less work participation and leveling of women's long-term earnings. Management of bladder symptom impact on nonwork related activities and depressive symptomatology may improve women's work outcomes.
Authors: Laura M Bogart; Marika J Suttorp; Marc N Elliott; J Quentin Clemens; Sandra H Berry Journal: Qual Life Res Date: 2011-12-07 Impact factor: 4.147
Authors: Sandra H Berry; Marc N Elliott; Marika Suttorp; Laura M Bogart; Michael A Stoto; Paul Eggers; Leroy Nyberg; J Quentin Clemens Journal: J Urol Date: 2011-06-16 Impact factor: 7.450
Authors: Eric Q Wu; Howard Birnbaum; Milena Mareva; Andrew Parece; Zihong Huang; David Mallett; Haya Taitel Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981
Authors: Kurt Kroenke; Tara W Strine; Robert L Spitzer; Janet B W Williams; Joyce T Berry; Ali H Mokdad Journal: J Affect Disord Date: 2008-08-27 Impact factor: 4.839
Authors: J Quentin Clemens; Richard T Meenan; Maureen C O'Keeffe Rosetti; Terry Kimes; Elizabeth A Calhoun Journal: Urology Date: 2008-03-10 Impact factor: 2.649
Authors: Siobhan Sutcliffe; Catherine S Bradley; James Quentin Clemens; Aimee S James; Katy S Konkle; Karl J Kreder; Hing Hung Henry Lai; Sean C Mackey; Cody P Ashe-McNalley; Larissa V Rodriguez; Edward Barrell; Xiaoling Hou; Nancy A Robinson; Chris Mullins; Sandra H Berry Journal: Int Urogynecol J Date: 2015-03-20 Impact factor: 2.894
Authors: Siobhan Sutcliffe; Robert Gallop; Hing Hung Henry Lai; Gerald L Andriole; Catherine S Bradley; Gisela Chelimsky; Thomas Chelimsky; James Quentin Clemens; Graham A Colditz; Bradley Erickson; James W Griffith; Jayoung Kim; John N Krieger; Jennifer Labus; Bruce D Naliboff; Larissa V Rodriguez; Suzette E Sutherland; Bayley J Taple; John Richard Landis Journal: BJU Int Date: 2019-05-29 Impact factor: 5.588
Authors: Lejian Huang; Jason J Kutch; Benjamin M Ellingson; Katherine T Martucci; Richard E Harris; Daniel J Clauw; Sean Mackey; Emeran A Mayer; Anthony J Schaeffer; A Vania Apkarian; Melissa A Farmer Journal: Pain Date: 2016-12 Impact factor: 7.926
Authors: Patrick Juliebø-Jones; Karin M Hjelle; Jannike Mohn; Gigja Gudbrandsdottir; Ingunn Roth; Adeel Asghar Chaudhry; Anne Kvåle Bergesen; Christian Beisland Journal: Adv Urol Date: 2022-01-10